Allen Moton

Allen Moton, PharmD, PMP, currently serves as the Executive Director of Clinical Development at Axsome Therapeutics, Inc., overseeing clinical research, medical monitoring, safety, and medical writing since December 2022. Previously, Allen held prominent roles at Bristol Myers Squibb, leading pharmacovigilance for immunology, neuroscience, and hematology-oncology from November 2019 to December 2022, following a merger with Celgene, where leadership in hematology trial safety was maintained. Allen's career includes senior director positions at Celgene and Molecular Templates, managing safety and clinical operations for oncology products. Early experiences at Novartis involved overseeing multinational clinical trials for respiratory conditions, while foundational roles at Schering-Plough Research Institute and Pfizer focused on clinical pharmacology and drug development across various therapeutic areas. Allen earned a Doctor of Pharmacy degree from Xavier University of Louisiana.